← Back to Fund Radar

Fund page

GESTION BOUTIQUE VII, FI

Category
Latest period
H2 2025
Positions
7

Portfolio as of 2025-12-31. Source: periodic filing with the CNMV. View original filing (PDF)

Full portfolio

Every position in the latest periodic filing, largest weight first. Aggregates ("other equities...") are baskets of small positions the filing itself does not break out line by line.

7
Company Type Country Weight Price
BANCO INVERSIS, S.A. ES0000012O67 · EUR Adquisicion Temporal Activos ES 4.37%
PARTICIPACIONES|ETC Source Physic GP IE00B579F325 · EUR Renta Variable Cotizada IE 3.08%
ACCIONES|Wisdomtree Issuer X GB00BJYDH287 · USD Renta Variable Cotizada GB 1.88%
ACCIONES|ASML Holding Nv NL0010273215 · EUR Renta Variable Cotizada NL 0.86%
ACCIONES|Berkshire Hathaway US0846707026 · USD Renta Variable Cotizada US 0.77% 495.82 USD
ACCIONES|Accs. Grifols S.A. ES0171996087 · EUR Renta Variable Cotizada ES 0.53% 9.91 EUR
ACCIONES|WisdomTree Phy.Gold GB00BJYDH394 · EUR Renta Variable Cotizada GB 0.51%

This period's moves

H2 2025 vs H1 2025 (estimated)

New: 5 Exits: 6 Increases: 2 Cuts: 0
+ BANCO INVERSIS, S.A.

Enters the portfolio at 4.37% weight.

View company page →
+ ACCIONES|ASML Holding Nv

Enters the portfolio at 0.86% weight.

View company page →
+ ACCIONES|Berkshire Hathaway

Enters the portfolio at 0.77% weight.

Berkshire Hathaway Inc., together with its subsidiaries, engages in the insurance, freight rail transportation, and utility businesses. The company provides property, casualty, life, accident, and health insurance and reinsurance; operates railroad systems in North America; generates, transmits, stores, and distributes electricity from natural gas, coal, wind, solar, hydroelectric, nuclear, and geothermal sources; operates natural gas distribution and storage facilities, interstate pipelines, liquefied natural gas facilities, and compressor and meter stations; and holds interest in coal mining assets. It manufactures boxed chocolates and other confectionery products; specialty chemicals, metal cutting tools, and components for aerospace and power generation applications; prefabricated and site-built residential homes, flooring products; insulation, roofing, and engineered products; building and engineered components; paints and coatings; and bricks and masonry products, as well as offers manufactured and site-built home construction, and related lending and financial services. In addition, the company provides recreational vehicles, apparel, footwear, toys, jewelry, custom picture framing products, alkaline batteries, logistics services, and professional aviation training and shared aircraft ownership programs; castings, forgings, fasteners/fastener systems, aerostructures, and precision components; and cobalt, nickel, and titanium alloys. Further, it distributes televisions and information, and grocery and non-food consumer products; franchises and services quick service restaurants; and distributes electronic components. Additionally, it retails automobiles; furniture, bedding, and accessories; household appliances, electronics, and floor coverings; watches, home decor and repair services; sells kitchenware; and motorcycle clothing and equipment. The company was incorporated in 1998 and is headquartered in Omaha, Nebraska.

View company page →
+ ACCIONES|Accs. Grifols S.A.

Enters the portfolio at 0.53% weight.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

View company page →
+ ACCIONES|WisdomTree Phy.Gold

Enters the portfolio at 0.51% weight.

View company page →
− BANCO INVERSIS, S.A.

Leaves the portfolio; it was 8.45% of weight.

− BANCO INVERSIS, S.A.

Leaves the portfolio; it was 8.45% of weight.

− BANCO INVERSIS, S.A.

Leaves the portfolio; it was 8.45% of weight.

− BANCO INVERSIS, S.A.

Leaves the portfolio; it was 8.45% of weight.

− BANCO INVERSIS, S.A.

Leaves the portfolio; it was 8.45% of weight.

− BANCO INVERSIS, S.A.

Leaves the portfolio; it was 8.45% of weight.

▲ ACCIONES|Wisdomtree Issuer X

Goes from 1.17% to 1.88%.

View company page →
▲ PARTICIPACIONES|ETC Source Physic GP

Goes from 2.43% to 3.08%.

View company page →

Fixed income

Declared FI exposure
243,000 €
% of portfolio
4.4%
Positions
1
Issuers
0
Sovereign: 0 € Corporate: 0 € Repos / treasury management: 243,000 €

Maturity ladder

Observed contractual maturity of each position, repos excluded. Matured/≤3 months includes bonds maturing in the first days after the period close.

Maturity Positions Exposure %
Matured or ≤3 months 0 0 € 0.0%
3-6 months 0 0 € 0.0%
6-12 months 0 0 € 0.0%
1-2 years 0 0 € 0.0%
2-5 years 0 0 € 0.0%
5-10 years 0 0 € 0.0%
> 10 years 0 0 € 0.0%
Unknown 0 0 € 0.0%

Disclaimer

This is not financial advice. The portfolio comes from the periodic report the fund files with the CNMV and lags the real close of the period: it is a snapshot of the end of each half-year, not a real-time portfolio.